Search research articles
Contact Us
Filters
Showing results (1-10 of 127) with videos related to
Page
of 13
Sort By:
Ebiomedicine
|
January 19, 2019
Ageing as a druggable process: Moving forward
Francesco Prattichizzo
Diabetes Research and Clinical Practice
|
February 2, 2020
The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive
Francesco Prattichizzo
Diabetes Care
|
December 22, 2022
Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448
Antonio Ceriello, Francesco Prattichizzo
Lancet (London, England)
|
January 4, 2025
The legacy effect of hyperglycaemia in type 2 diabetes
Francesco Prattichizzo, Antonio Ceriello
Journal of Diabetes and Its Complications
|
April 26, 2021
Pharmacological management of COVID-19 in type 2 diabetes
Antonio Ceriello, Francesco Prattichizzo
The Lancet. Diabetes & Endocrinology
|
February 19, 2021
Positioning newer drugs in the management of type 2 diabetes
Francesco Prattichizzo, Antonio Ceriello
Diabetes/Metabolism Research and Reviews
|
July 9, 2021
Is time ready for combination therapy at diagnosis of type 2 diabetes?
Francesco Prattichizzo, Antonio Ceriello
Cardiovascular Diabetology
|
May 8, 2021
Variability of risk factors and diabetes complications
Antonio Ceriello, Francesco Prattichizzo
The New England Journal of Medicine
|
May 8, 2024
Microplastics and Nanoplastics in Atheromas. Reply
Raffaele Marfella, Francesco Prattichizzo
European Heart Journal
|
December 19, 2025
Hygiene measures and persistent adherence to SGLT-2 inhibitors minimize risks and maximize cardiorenal protection
Francesco Cosentino, Francesco Prattichizzo, Antonio Ceriello
Page
of 13
Search research articles
Search
Showing results (1-10 of 127) with videos related to
Sort By:
Page
of 13
Ebiomedicine
|
January 19, 2019
Ageing as a druggable process: Moving forward
Francesco Prattichizzo
Diabetes Research and Clinical Practice
|
February 2, 2020
The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive
Francesco Prattichizzo
Diabetes Care
|
December 22, 2022
Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448
Antonio Ceriello, Francesco Prattichizzo
Lancet (London, England)
|
January 4, 2025
The legacy effect of hyperglycaemia in type 2 diabetes
Francesco Prattichizzo, Antonio Ceriello
Journal of Diabetes and Its Complications
|
April 26, 2021
Pharmacological management of COVID-19 in type 2 diabetes
Antonio Ceriello, Francesco Prattichizzo
The Lancet. Diabetes & Endocrinology
|
February 19, 2021
Positioning newer drugs in the management of type 2 diabetes
Francesco Prattichizzo, Antonio Ceriello
Diabetes/Metabolism Research and Reviews
|
July 9, 2021
Is time ready for combination therapy at diagnosis of type 2 diabetes?
Francesco Prattichizzo, Antonio Ceriello
Cardiovascular Diabetology
|
May 8, 2021
Variability of risk factors and diabetes complications
Antonio Ceriello, Francesco Prattichizzo
The New England Journal of Medicine
|
May 8, 2024
Microplastics and Nanoplastics in Atheromas. Reply
Raffaele Marfella, Francesco Prattichizzo
European Heart Journal
|
December 19, 2025
Hygiene measures and persistent adherence to SGLT-2 inhibitors minimize risks and maximize cardiorenal protection
Francesco Cosentino, Francesco Prattichizzo, Antonio Ceriello
Page
of 13